Drug approvals this year have reflected the trend in clinical development of biologics shifting from intravenous to ...
TSRA-196 is a potential one-time treatment to precisely correct the genetic mutation underlying AATD, with Investigational New Drug filing expected by the end of the year Tessera to receive $150 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback